Maintenance therapy in bipolar disorder (BD) is usually required to prevent relapses and improve residual symptoms. Therefore, in this study, we describe patterns of pharmacological maintenance treatment and identify associated clinical features. This prospective multicentre epidemiological study recruited a cohort of 739 consecutive out-patients with clinically stable BD. Clinical stability was assessed at baseline with the Clinical Global Impression scale for BD and depressive symptoms with the Hamilton Depression Rating Scale. Psychotropic medications were classified and analysed according to their mechanism as well as use. Logistic regression models were used to examine the associations between pharmacological strategies and clinical features. Longer time since last episode [odds ratio (OR) 1.002, p<0.0001] and family history of psychiatric disorders (OR 1.911, p=0.028) were associated with lithium in monotherapy ; manic polarity of the most recent episode (OR 3.300, p=0.006) and longer duration of clinical stability (OR 1.009, p=0.034) with antipsychotic in monotherapy ; depressive polarity of the most recent episode (OR 2.567, p=0.003) and bipolar II disorder diagnosis (OR 2.278, p=0.008) with antidepressant combination ; no ongoing psychiatric co-morbidity (OR 0.230, p=0.004) with lithium and anticonvulsant ; manic polarity of the most recent episode (OR 3.774, p<0.0001) with lithium and antipsychotic ; manic polarity of the most recent episode (OR 2.907, p=0.028) with lithium, anticonvulsant and antipsychotic. The pharmacological patterns followed published recommendations, except for the excessive use of antidepressants. This study reveals clinical factors closely related to prescription patterns.
Introduction
Bipolar disorder (BD) is a major mental health issue associated with considerable morbidity and mortality (Hirschfeld & Vornik, 2005) . It is characterized by recurrent episodes of mania, hypomania, depression and mixed states separated by periods of relative euthymia. Treatments that can stabilize the acute mood swings in BD are available as is maintenance treatment. Since BD is a recurrent illness, a long-term prophylactic treatment is usually recommended (Suppes et al. 1991) and needed to uphold the initial therapeutic success. Maintenance therapy is expected to prevent relapses and reduce threshold symptoms, risk of suicide, cycle frequency and mood instability (APA, 2002) . However, psychiatrists do not only assess the therapeutic effect but also the tolerability since it may be a long-term or even lifelong therapy (Vieta & Rosa, 2007) .
Maintenance therapy is usually required in order to improve functioning and maintain quality of life since functional impairment has been related to residual symptoms (Joffe et al. 2004 ; MacQueen et al. 2000 ; Rosa et al. 2009 ; Wolf & Mü ller-Oerlinghausen, 2002) . Patients with subclinical depressive symptoms present three to six times more functional impairment in various domains, such as work, housework and relationships with relatives and friends, than those who do not have these symptoms (Bonnín et al. 2012 ; Rosa et al. 2011) . Therefore, the importance of identifying and appropriately treating these symptoms is widely acknowledged and thus patients can obtain complete disease remission and thereby improve their clinical outcomes in both the medium and long term (Perlis et al. 2006) .
Several guidelines are available for the treatment of BD, covering both management of acute mood episodes and long-term prophylaxis (APA, 2002 ; Frye et al. 2011 ; Goodwin, 2009 ; Grunze et al. 2010 ; National Collaborative Centre for Mental Health, 2006 ; Suppes et al. 2005 ; Yatham et al. 2009 ). Although continuous efforts have been made to improve the management of this disease (Murru et al. 2011 ; Popovic et al. 2011) , it is important to describe the current pharmacological strategies in clinical practice since BD may be one of the areas with a wide gap between evidence-based treatment as recommended by the guidelines and the actual hands-on clinical approach (Fountoulakis et al. 2005 ; Vieta & Rosa, 2007) . According to the WHO, usual clinical practice should be assessed by means of drug utilization studies, which include an analysis of the prescription and use of medicinal products in the community with the final objective of defining optimal therapeutic practice (WHO Experts Committee, 1977) .
The relevance of subclinical symptoms in long-term evolution led us to conduct a study in a large sample of clinically stable BD patients who attended a community health services setting. The main objectives were to obtain a cross-sectional estimation of the presence of subclinical depressive symptoms as reported elsewhere (Vieta et al. 2010a) and to describe maintenance drug utilization patterns, as reported herein. Scarce studies have focused on prescription in community health services. Moreover, most have centred on treatment patterns during acute phases of BD (Bellantuono et al. 2007 ; Montoya et al. 2010) or studies of mixed samples (Baldessarini et al. 2007 ; Ghaemi et al. 2006) . Since clinical trials are not suitable for understanding treatment patterns, our objective with this naturalistic study was to explore the pharmacological patterns with relevant clinical features of BD.
Method
This was a prospective 16-week epidemiological study of a cohort of consecutive out-patients with clinically stable BD. The project was called SIN-DEPRES and was conducted at 88 community-based mental health services and private clinics across several geographical regions within Spain from April 2006 to March 2007. The sites involved were selected to make them representative of prescription patterns across Spain at the time of the survey by selecting eight consecutive patients from each centre and including a certain number of centres according to the population of the region. Fifteen centres were private psychiatric outpatient clinics and the rest community-based mental health centres. To really focus on maintenance treatment, acutely ill patients were excluded. Further details on the methodology are available elsewhere (Vieta et al. 2010a, b) .
Subjects
The inclusion criteria for patients in this study were : aged o18 yr ; well-established diagnosis of BD according to Diagnostic and Statistical manual of Mental Disorders criteria (DSM-IV) ; clinical stability for at least the previous month ; presence of at least one acute affective episode during the 5 yr prior to inclusion in the study ; given informed consent. Clinical stability was defined as a score of 'normal' or 'minimal ' on both the depression and mania items of the Modified Clinical Global Impressions Scale for bipolar disorder (CGI-BP-M ; Spearing et al. 1997 ; Vieta et al. 2002) . Patients were excluded if no reliable information was available at the centre, they presented an acute affective episode at inclusion or suffered from another serious psychiatric condition, drug addiction, disorders of the central nervous system, organic brain disease, head trauma, dementia or an uncontrolled serious medical condition that could account for secondary depression (e.g. hypothyroidism). Patients who had suffered a single acute episode of BD and those participating in clinical trials were excluded.
The study included a sample of 761 BD I and II patients, 739 of whom were included in the final analysis. Those excluded (n=22) failed to meet the stability criteria, according to CGI-BP-M, did not present with acute episodes within the last 5 yr or suffered from co-morbid medical conditions, such as hypothyroidism. In total, 733 of them were under treatment and were assessed in the study.
The study was approved by the Independent Ethics Committee of one of the participating centres, Hospital Clinic de Barcelona. All participants were informed about the study procedures and provided their written informed consent prior to inclusion.
Procedure
Data were obtained from the patients by means of a clinical interview and a psychiatric examination. The interview obtained information about sociodemographic and clinical data, including history of psychiatric disorders in first-degree relatives, history of treatments received and the degree of compliance and satisfaction with the treatment.
In order to determine clinical stability at baseline, all patients were assessed with the CGI-BP-M, taking into consideration the last month period (Spearing et al. 1997 ; Vieta et al. 2002) . The 17-item Hamilton Depression Rating Scale (HAMD-17 ; Bobes et al. 2003 ; Maier et al. 1988) was also administered to evaluate the presence and severity of depressive symptoms at enrolment. In this context ' mild depression ' at baseline was defined as a total score between 7 and 17 on the HAMD-17. Depressive symptoms were likewise evaluated at enrolment and end of study, using the Montgomery-Asberg Depression Rating Scale (Lobo et al. 2002 ; Montgomery & Asberg, 1979) .
The recorded medication included all treatments being followed by the patient, including all drugs at prescribed daily doses. The patient's pharmacological maintenance treatment at baseline and for 4 months was encoded according to the Anatomical Therapeutic Chemical classification system (WHO, 2009) . In order to study the pharmacological maintenance patterns of prescription, the medication prescribed at baseline was investigated in this study. Descriptive lists of drug utilization patterns relating to all assessable patients were produced. Treatment adherence was also documented according to the investigator's judgement based on the doses missed during a standard week (Weiden et al. 2004) . Finally, the investigator recorded the patient's satisfaction with treatment on a 5-point Likert scale, ranging from 'not at all ' to ' extremely satisfied'.
Data analysis
The sample size, as described elsewhere (Vieta et al. 2010a, b) , was calculated in order to determine the prevalence of depressive symptoms among clinically stable BD out-patients.
In order to analyse the relationship between prescription patterns and clinical features of the disorder, therapeutic strategies were defined a priori, considering the generic therapeutic classification of agents, regardless of their approval for BD treatment : lithium, anticonvulsant or antipsychotic agents in monotherapy, combination of lithium with either anticonvulsants or antipsychotics or anticonvulsants with antipsychotics, combination of all three agents and combination with antidepressants. For this analysis, pharmacological strategies were classified as mutually exclusive. Gabapentin, topiramate and clonazepam were not considered anticonvulsant treatment prescribed for BD because of lack of evidence base for their use in this condition.
The clinical variables considered for the analysis were age, gender, marital status, educational level, occupational status, living conditions, BD type, clinical course of rapid cycling or seasonal pattern, past depressive episodes, polarity of the most recent episode according to DSM-IV-TR, age at first episode, number of episodes per year, time elapsed since the last episode, duration of the most recent episode, time elapsed since the last depressive episode, duration of the most recent depressive episode, duration of clinical stability, live events since last assessment, ongoing psychiatric co-morbidity, first degree relative psychiatric history and presence of depressive symptoms.
To analyse the differences between the described variables in each pharmacological strategy, analysis of variance or x 2 tests were used, as appropriate, or their respective non-parametric tests if data did not fit a normal distribution. Then a logistic regression model was constructed for each pre-defined strategy to ascertain which clinical factors were associated with each strategy. The models were created according to Hosmer and Lemeshow advice to introduce one parameter for each 10 observed cases (Hosmer & Lemeshow, 2000) .
Statistic analysis was conducted using the software Statistical Package for Social Sciences version 18.0 (SPSS Inc., USA). All p values reported were two tailed. Statistical significance was defined as p<0.05.
Results

Sample characteristic
Most of the patients were diagnosed with BD type I (n=537, 72.7 %) (Table 1) and 88.2 % (n=652) had had a previous depressive episode. More than half of the (Vieta et al. 2010a ).
Patterns of drug treatment
Most of the sample was under an antidepressant association strategy (n=284, 38.7 %) ( Table 2 ). Antidepressant combination patterns and types of antidepressants were classified according to the therapeutic strategies in Table 3 . The combination strategies without antidepressants (n=302, 41.2 %) were more prevalent than monotherapy (n=147, 20.0 %). The most prevalent monotherapy was lithium (n=76, 10.4 %). 
Relationship between prescription patterns and clinical features of BD
The results of the logistic regressions showed different factors that were significantly associated with each pharmacological strategy (Table 4) .
The time elapsed since the last episode [odds ratio (OR) 1.002, 95 % confidence intervals (CI) 1.001-1.002, p<0.0001] and a family history of psychiatric disorder (OR 1.911, 95 % CI 1.071-3.412, p=0.028) were significantly associated with the possibility of following maintenance treatment with lithium in monotherapy. Age at enrolment was inversely related to the use of lithium in monotherapy (OR 0.975, 95 % CI 0.954-0.997, p=0.023). No significant relationships were detected in the use of anticonvulsant in monotherapy. Manic polarity of the most recent episode (OR 3.300, 95 % CI 1.497-9.346, p=0.006) and duration of clinical stability (OR 1.009, 95 % CI 1.001-1.017, p=0.034) were significantly associated with the possibility of following maintenance treatment with an Finally, the use of combined treatment with the three agents as maintenance therapy was significantly associated with manic polarity of the most recent episode (OR 2.907, 95 % CI 1.124-7.519, p=0.028).
Discussion
In this study several clinical features of bipolar patients were related to patterns of pharmacological maintenance strategies. Family history of psychiatric disorders, longer time since last episode and youth at the time of enrolment were associated with lithium monotherapy, manic polarity of the most recent episode and longer duration of clinical stability were associated with antipsychotic in monotherapy ;
depressive polarity of the most recent episode, BD type II diagnosis, and older age at the time of enrolment with antidepressant association strategy ; older age at first episode and no ongoing psychiatric comorbidity with lithium and anticonvulsant strategy ; manic polarity of the most recent episode with lithium and antipsychotic strategy ; youth at enrolment with anticonvulsant and antipsychotic strategy ; and finally manic polarity of the most recent episode was associated with maintenance treatment with lithium, anticonvulsant and antipsychotic therapy. Manic polarity of the most recent episode was related to maintenance treatment with antipsychotics in monotherapy, in combination with lithium or in combination with lithium and anticonvulsants. These results are in accordance with current guidelines, which recommend an approach to bipolar maintenance treatment based on the concept of predominant polarity (Colom et al. 2006 ; Goodwin, 2009 ; Nivoli et al. 2011b ; Yildiz et al. 2011) or the nature of the preceding acute episode (Suppes et al. 2005) .
On the other hand, depressive polarity of the most recent episode was associated with antidepressants combined with maintenance treatment. It is a matter of debate whether antidepressants should be prescribed in BD or not, particularly in long-term treatment, (Nivoli et al. 2011a ; Valentí et al. 2011 ; Vieta et al. 2010b ). On one hand, some guidelines do not recommend their use (APA, 2002 ; Frye et al. 2011 ; Yatham et al. 2009 ). Despite accepting that adjunctive antidepressants may be effective in the acute treatment of BD, it has been suggested that antidepressants do not appear to provide any additional benefit in longterm treatment of bipolar depression (Frye et al. 2011) . For this reason, the NICE guidelines limit the use of treatment is a widely spread clinical practice (Baldessarini et al. 2007) and suggests that there is not sufficient evidence to recommend the discontinuation of antidepressants (Goodwin, 2009 ). In addition, a significant association in the same pharmacological strategy was found with the BD type II diagnoses. Given the major burden of the disease imposed by chronic depressive symptoms and recurrent depressive episodes in BD II (Judd et al. 2003 ; Solé et al. 2012) , antidepressant prescription may be foreseeable .
In the maintenance treatment with lithium in monotherapy, family history of psychiatric disorder seemed to be related to this strategy. It is commonly known that response to a given drug by a patient's relative is an important indicator for selecting the optimal treatment. In the case of lithium, familial clustering of response to treatment reportedly gave a significantly better response to lithium prophylaxis among relatives (Grof et al. 2002 ; Mendlewicz et al. 1973) .
Moreover, youth at the time of enrolment was associated with lithium in monotherapy as well as with a combination of anticonvulsants and antipsychotics in contrast to the association between old age at enrolment with the antidepressant combination. These relationships could be explained as young patients are presumed not to have suffered the disorder for long. Therefore, neuroprogression in the disorder may not have progressed too long and firstline treatments, such as the former, which are initially prescribed, could still be effective (Yatham et al. 2009 ) in contrast to the latter, which is usually prescribed as a last resort.
Along the same lines, lithium is reported to better prevent relapses when introduced within the first 10 yr of illness (Franchini et al. 1999) . Thus, patients under lithium monotherapy may show less severe evolution, which would not require treatment changes. For this reason patients under lithium monotherapy may present with a longer time since last episode.
The combination strategy with lithium and anticonvulsants was significantly associated with older age at first episode. It could be hypothesized that this may be due to a delay in the diagnosis in this subsample, a further progression of the disorder and, consequently, an ineffective monotherapy treatment (Hirschfeld et al. 2003) . Moreover, this pharmacological strategy was inversely associated with psychiatric co-morbidity. We consider that this relationship results from the exclusion of anticonvulsants in this study, such as gabapetin, topiramate and clonazepam, which are generally used in other psychiatric disorders and in co-morbid conditions. With regard to antipsychotics, an association was found between antipsychotic monotherapy and the duration of clinical stability, highlighting the suitability to use these drugs in maintenance treatment (Popovic et al. 2012 ; Vieta et al. 2011) .
The present study has some limitations. Drug indications and prescription patterns vary across countries. However, a great effort was made to ensure the representativity of the sample across out-patient mental health settings in Spain. In fact, similar results at the prescription pattern were found in the different settings. Nevertheless, the results obtained in our country may not be fully generalizable to other countries, where attention and services to the patients may be differently distributed. Furthermore, it is important to bear in mind that this is a cross-sectional study and does not give a relationship of causality between the prescription pattern and clinical features. However, this study on maintenance treatment in BD may shed some light on this barely unexplored field. The results confirm that, in general, prescription patterns in BD are in line with published recommendations, except for the excessive use of antidepressants. This study also reveals clinical factors that may be closely related to prescription patterns, for which the evidence-based treatment may or may not be available, but which may help to build not only evidence-based but also experience-based guidelines.
